Mergers & Acquisitions Mergers & Acquisitions

Hypera tells CADE pandemic hasn't affected deal with Boehringer

By Ana Paula Candil
  • 20 Jul 2020 17:14
  • 20 Jul 2020 17:40
Hypera has told the Brazilian competition authority that the pandemic hasn't affected its plans to buy and invest in Boehringer Ingelheim's antispasmodics and analgesics brands, but "reinforced" the need to "urgently" close the transaction, which involves the acquisition of a medicine that relieves symptoms of Covid-19. 

Hypera is planning to buy Boehringer Ingelheim's

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News